288 assets in Lymphoma

Therapeutic assets addressing Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Lymphoma	National Cancer Institute (NCI)	P2	B (60)
Oxaliplatin Lymphoma	Brown University	P3	B (60)
Palifermin Lymphoma	Center for International Blood and Marrow Transplant Research	P3	B (60)
Regramostim Lymphoma	Ou Bai, MD/PHD	P4	B (60)
Trastuzumab Emtansine Lymphoma	Memorial Sloan Kettering Cancer Center	P2	B (60)
Vinorelbine Ditartrate Lymphoma	Memorial Sloan Kettering Cancer Center	P3	B (60)
Clofarabine Lymphoma	Memorial Sloan Kettering Cancer Center	P2	B (59)
Fluconazole Lymphoma	Hutchmed	P3	B (59)
Mechlorethamine Lymphoma	Memorial Sloan Kettering Cancer Center	P3	B (59)
Vedolizumab Lymphoma	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P3	B (59)
Abatacept Recombinant Lymphoma	Center for International Blood and Marrow Transplant Research	P3	B (58)
Dexrazoxane Lymphoma	Beth Israel Deaconess Medical Center	P2	B (58)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Lymphoma	National Cancer Institute (NCI)	P2	B (58)
Peg-Rhg-Csf Lymphoma	Ou Bai, MD/PHD	P4	B (58)
Plerixafor Lymphoma	Peking University	P4	B (58)
Polatuzumab Vedotin Lymphoma	Beth Israel Deaconess Medical Center	P2	B (58)
Baricitinib Lymphoma	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2/3	B (57)
Daratumumab Lymphoma	M.D. Anderson Cancer Center	P2	B (57)
Entinostat Lymphoma	National Cancer Institute (NCI)	P2	B (57)
Fexagratinib Lymphoma	National Cancer Institute (NCI)	P2	B (57)
Ketorolac Lymphoma	St. Louis University	P3	B (57)
Tazemetostat Lymphoma	Fudan University	P2	B (57)
Tocilizumab Lymphoma	Hoffmann-La Roche	P3	B (57)
Abrysvo Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Afluria Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Atezolizumab Lymphoma	Glenmark Specialty S.A.	P2	B (56)
Capecitabine Lymphoma	Huiqiang Huang	P2	B (56)
Fluarix Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Flucelvax Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Flulaval Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Fluzone Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Heplisav-B Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Ipilimumab Lymphoma	National Cancer Institute (NCI)	P2	B (56)
Isatuximab Lymphoma	Divaya Bhutani	P2	B (56)
Mosunetuzumab Lymphoma	Inhye Ahn	P2	B (56)
pcv20 Lymphoma	M.D. Anderson Cancer Center	P4	B (56)
Pembrolizumab Lymphoma	Merck Sharp & Dohme LLC	P2	B (56)
Pfizer-Covid-19 Vaccine Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Ppsv23 Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Prevnar 13 Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Prevnar 20 Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Recombinant Respiratory Syncytial Virus Pre-Fusion F Protein Antigen Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Selinexor Lymphoma	Second Affiliated Hospital of Soochow University	P2	B (56)
Shingrix Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Zanubrutinib Lymphoma	Inhye Ahn	P2	B (56)
Amdizalisib Lymphoma	Hutchmed	P2	CCC (55)
Itraconazole Lymphoma	Hutchmed	P1	CCC (55)
Apixaban Lymphoma	Medical University of Gdansk	P3	CCC (54)
Duvelisib Lymphoma	SecuraBio	P3	CCC (54)
Hpc, Cord Blood Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (54)

Showing 51 to 100 of 288 assets

PreviousPage 2 of 6Next